



Beta-blockers in COPD: time for reappraisal

Journal:	<i>European Respiratory Journal</i>
Manuscript ID	ERJ-01847-2015.R2
Manuscript Type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Lipworth, Brian; University of Dundee, Asthma & Allergy Research Group Wedzicha, Jadwiga; Imperial College London, Airways Disease Section, National Heart and Lung Institute Devereux, Graham; University of Aberdeen, Applied Health Sciences Vestbo, Jørgen; University of Manchester, Centre for Respiratory Medicine and Allergy Dransfield, Mark; University of Alabama at Birmingham, Pulmonary, Allergy and Critical Care
Key Words:	COPD, beta-blocker, coronary artery disease, heart failure, Exacerbations

Beta-blockers in COPD: time for reappraisal

Authors: Dr Brian Lipworth¹, Prof Jadwiga Wedzicha², Prof Graham Devereux³,
Professor Jørgen Vestbo⁴, Dr Mark T. Dransfield⁵

Affiliations: ¹Scottish Centre for Respiratory Research, Ninewells Hospital and
Medical School, University of Dundee, Scotland, UK, ²Airways Disease
Section, National Heart & Lung Institute, Imperial College London, London, UK,
³Applied Health Sciences, University of Aberdeen, Aberdeen, UK, ⁴Centre for
Respiratory Medicine and Allergy, University Hospital South Manchester NHS
Foundation Trust, University of Manchester, UK, ⁵Lung Health Center, Division of
Pulmonary, Allergy and Critical Care Medicine, University of Alabama at
Birmingham, Alabama, USA; Birmingham VA Medical Center, Alabama, USA

Correspondence: Dr Brian Lipworth, Scottish Centre for Respiratory Research,
Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY
b.j.lipworth@dundee.ac.uk

Manuscript word count: ~~3138~~3141

Author contributions: All authors contributed to the literature search, writing and
presentation of the manuscript, and approval of the final version.

“Take Home” message:

Beta-blockers (BB) are used for heart failure and after myocardial infarction but remain underused in COPD despite recommendations in guidelines.

~~Prospective trials are needed to assess whether BB reduce exacerbations and deaths in COPD~~

Abstract

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain underused due to concerns regarding potential bronchoconstriction even with cardio-selective drugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in older patients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy. Several retrospective observational studies have shown impressive reductions in mortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer

1
2
3 benefits on mortality and exacerbations in all patients with COPD including those
4
5 with silent cardiovascular disease where the situation is less clear.
6
7

8
9 **Key words:** COPD, beta-blocker, coronary artery disease, heart failure,
10
11 exacerbations
12
13

14
15
16 **Abstract word count:** 198
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic obstructive pulmonary disease (COPD) is one of the world's leading causes of morbidity and is now the third leading cause of mortality amounting to 3 million deaths in 2010.[1, 2] Exacerbations in particular account for up to three quarters of the total costs due to COPD,[3] with attributable costs exceeding 30 billion USD.[4] A recent COPD taskforce statement [5] identified an unmet need in terms of finding drugs to treat common co-morbidities specifically mentioning the putative effects of beta-blockers on the cardiovascular burden and its associated impact on mortality. Cardiovascular comorbidity is common in patients with COPD due to smoking in addition to other shared risks including genetic susceptibility, systemic inflammation and ageing.[6] The prevalence of COPD in patients with heart failure ranges from 11-52% in North American patients and 9-41% in European patients.[7] The purpose of this article is to critically reappraise the current knowledge regarding beta-blockers in COPD looking at the current evidence for their therapeutic index and how this relates to management guidelines.

We have not attempted a systematic review or meta-analysis as described elsewhere,[8-10] but rather highlighted the key areas of clinical relevance for physicians who treat patients with COPD. In this article we have 1) considered the putative link between COPD and the heart in terms of potential targets for beta-blockers, 2) reviewed retrospective data linking use of beta-blockers to reduced exacerbations and mortality, 3) examined the unmet need for use of beta-blockers in patients with COPD and both known, and potentially unknown cardiovascular disease, 4) evaluated which beta-blocker to use based on their pharmacology and

1
2
3 impact on pulmonary function, and 5) attempted to draw conclusions about the
4
5 current clinical use of beta-blockers in COPD.
6
7
8
9

10 **COPD and the heart (Figure 1 and Box 1)**

11
12 The main accepted clinical indications for the use of beta-blockers in COPD are for
13
14 patients post myocardial infarction and for patients with heart failure. However, the
15
16 presence of untreated or unrecognized (i.e. silent) cardiovascular disease may
17
18 contribute to mortality in COPD and may also be an underlying causative factor in
19
20 exacerbations which can be difficult to separate from respiratory etiologies.[6] [7] It is
21
22 also possible, if not likely, that the burden of cardiovascular disease may be under-
23
24 rated by pulmonologists when treating COPD patients because symptoms are
25
26 presumed to be primarily driven by airflow obstruction, especially during
27
28 exacerbations.
29
30
31

32
33 The prevalence of left ventricular systolic dysfunction ranges between 10-46% in
34
35 patients with COPD and though the occurrence of heart failure with preserved left
36
37 ventricular ejection fraction is less clear, estimates in patients with severe COPD are
38
39 as high as 90%.[7] The benefits of beta-blockers in patients with heart failure due to
40
41 left ventricular systolic dysfunction are well established from pivotal trials as well as
42
43 meta-analysis.[21-24] The challenge in COPD may be more with respect to
44
45 diagnosis of heart failure with echocardiography where image acquisition is difficult
46
47 due to lung hyperinflation.[25]
48
49

50
51 Beta-blockers only have proven benefits in patients post myocardial infarction but not
52
53 in stable coronary arterial disease.[11, 12] Nevertheless, the presence of coronary
54
55 calcium on chest CT scans is associated with mortality in COPD,[13] and known
56
57 coronary arterial disease is also associated with longer exacerbations, more
58
59
60

1
2
3 dyspnoea, lower health status and exercise capacity in stable patients with
4 COPD.[14] There is also an acute increase in arterial stiffness particularly during
5 infective exacerbations of COPD, along with increases in cardiac enzymes especially
6 in patients with coronary arterial disease;[15] one study found that one in twelve
7 patients admitted to hospital with an exacerbation of COPD met the criteria for a
8 myocardial infarction.[16] The presence of coronary heart disease in COPD along
9 with the adverse effects of hypoxaemia [17] may be compounded by the positive
10 chronotropic effects of concomitant inhaled beta-agonist therapy,[18, 19] further
11 compromising cardiac reserve. It has been shown that even a low dose of a beta-1
12 selective antagonist such as atenolol might protect against chronotropic, inotropic
13 and electrocardiographic effects of inhaled beta-agonists which are mediated by
14 cardiac beta₂ receptor stimulation.[20]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Another potential target is diastolic dysfunction though a meta-analysis suggests that the beneficial effects of beta-blockers in such patients are less clear cut.[26] Several factors may contribute to the occurrence of impaired diastolic function in COPD.

Firstly, patients with COPD also appear to have a higher left ventricular mass (hypertrophy) even in the absence of left ventricular dilatation. Secondly, lung hyperinflation in COPD may cause cardiac compression reducing both left ventricular and atrial filling even in the absence of raised pulmonary arterial pressure.[28-30]

These factors, may also be compounded by the negative effects of hypoxaemia on diastolic filling.[31] [17]

In addition to these COPD related risks, patients with the disease commonly have other co-morbidities such as coronary artery disease, hypertension and diabetes, which can all adversely affect diastolic function. This was addressed in a recent prospective longitudinal study of healthy young adults followed over 25 years, where

1
2
3 a fall in the ratio of forced expiratory volume in one second to forced vital capacity
4 (FEV₁/FVC) was associated with reduced left atrial size and cardiac output.[32] Left
5
6
7 ventricular end diastolic and end systolic wall stress measured by magnetic
8
9
10 resonance imaging (MRI) is associated with increasing severity of airflow obstruction
11
12 in patients with COPD and coexistent heart failure.[33] Impaired left ventricular filling
13
14 is clinically important because it can eventually produce left atrial enlargement which
15
16 is a key risk factor for atrial fibrillation and associated mortality during exacerbations
17
18 of COPD.[34] Furthermore, the presence of impaired diastolic filling in patients with
19
20 COPD is also related to impaired walking distance.[35] Thus, the absence of
21
22 benefits of beta-blockers in diastolic dysfunction may not apply in COPD and
23
24 deserved re-evaluation in this patient group.
25
26
27
28

29 **Effects of beta-blockers on mortality and exacerbations**

30
31
32 Due to the high cardiovascular comorbidity in COPD from smoking along with
33
34 increased sympathetic drive due to hypoxaemia,[36] beta-blockers have been
35
36 proposed as a cogent therapeutic intervention for their known cardio-protective
37
38 effects in addition to reducing heart rate and improving systolic and diastolic
39
40 dysfunction. One of the fundamental issues with regards to more widespread use of
41
42 beta-blockers in COPD is the concern regarding beta₂ receptor antagonism and
43
44 associated airway smooth muscle constriction which may even occur with cardio-
45
46 selective agents which exhibit preferential beta₁ blockade, especially in more
47
48 susceptible severe patients with impaired respiratory reserve. The risk-benefit
49
50 equation in COPD becomes more favorable for patients who already have overt
51
52 cardiac disease such as heart failure or post myocardial infarction, where beta-
53
54 blockers have proven protective effects.[11, 21] There are, however, no data as to
55
56
57
58
59
60

1
2
3 the putative beneficial effects of beta-blockers in ~~those the majority of~~ COPD patients
4 who may have concomitant silent coronary arterial~~heart~~ disease or heart failure.
5
6

7 Retrospective observational data have shown beneficial effects of beta-blockers in a
8 cohort of 5977 patients with COPD who were followed over a mean of 4.35 years
9 [37] where their use was associated with an overall 22% (95% confidence interval 8-
10 33) reduction in mortality. In a study b of 825 patients admitted to hospital for an
11 exacerbation of COPD, beta-blocker use among 142 patients was associated with a
12 61% (1-86) reduction in mortality.[38] Rutten et al showed 32% (17-44) and 29% (17-
13 40) reductions in mortality and exacerbations, respectively, conferred by taking beta-
14 blockers among 2230 patients with COPD followed up for a mean of 7.2 years.[39] In
15 a cohort study from Sweden of 4858 patients with COPD, those who were
16 discharged on a beta-blocker (84%) post myocardial infarction had 13% (2-22) lower
17 mortality.[40] In a retrospective report of 256 patients with COPD with either
18 coronary heart disease or heart failure, 58% were taking beta-blockers where there
19 was a 73% (50-85) reduction in the likelihood of being admitted to a hospital
20 emergency room.[41] In contrast, in an observational study using time dependent
21 analysis of 2249 severe oxygen dependent COPD patients there was a 19%
22 increase in mortality associated with taking beta-blockers.[42] However, in a
23 prospectively followed cohort of 3464 patients Bhatt et al found a 27% (10-40)
24 reduction in total exacerbations, while in GOLD 3/4 patients on home oxygen there
25 was a 67% reduction (42-81).[43]
26
27

28
29
30 In a 2012 meta-analysis of 9 retrospective cohort studies, the pooled estimate for
31 mortality reduction with beta-blockers was reported to be 31% (22-38).[8] In a
32 subsequent 2014 meta-analysis of 15 retrospective studies of 21,596 patients with
33 COPD, the pooled estimate for reduction in overall mortality conferred by beta-
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 blockers was 28% (17-37) and for exacerbations was 38% (18-58).[9] The reduction
4
5 in mortality was 36% (24-46) among the subgroup of patients (5 studies: 39%
6
7 weighting) with known coronary heart disease and 26% (7-42) in the subgroup with
8
9 known heart failure (3 studies: 18% weighting).
10

11 The beneficial effects of beta-blockers on exacerbations may involve other potential
12
13 non-cardiac mechanisms whereby beta-blockers could reduce COPD exacerbations.
14
15 In heart failure, use of cardioselective beta-blockers reduces systemic inflammatory
16
17 cytokine release such as IL-6 and alters leukocyte distribution which may also impact
18
19 inflammation during respiratory infections.[44] Beta-blockers have also been
20
21 reported to inhibit neutrophil chemotaxis and oxygen free radical production,[45]
22
23 while in human endothelial cells they have been reported to reduce the release of
24
25 endothelin-1, a bronchoconstrictor peptide implicated in the pathogenesis of COPD
26
27 exacerbations.[46, 47]
28
29
30

31 It is not possible to eliminate the possibility of residual confounding in the
32
33 observational studies suggesting beta-blockers may reduce exacerbations and
34
35 mortality in COPD and thus definitive randomized trials are needed. There is now a
36
37 planned placebo controlled trial powered for a reduction in exacerbations using
38
39 metoprolol over 1 year via the US COPD Clinical Research Network and funded by
40
41 the Department of Defense (Clinicaltrials.gov Identifier:NCT02587351).
42
43
44
45
46

47 This study will only exclude those patients with an absolute indication for beta-
48
49 blockers including an MI or revascularization procedure within three years or with an
50
51 ejection fraction <40%. However, it remains possible that this and similar studies
52
53 may run the risk of only including patients where beta-blockers are less efficacious.
54
55
56
57
58
59
60

The unmet cardiac need in COPD

Beta-blockers have an established position in the management of coronary artery disease while heart failure guidelines reinforce their use in patients with concomitant COPD.[51] Similarly, COPD management strategies also state that the benefits of selective beta-1 blocker treatment in heart failure clearly outweigh any potential risk associated with treatment even in patients with severe COPD.[52] Despite this guidance there is a reluctance to prescribe even cardio-selective beta-blockers in COPD, even in the presence of known cardiac disease because of persistent concerns regarding potential bronchoconstriction, especially in more severe patients. In a cohort from Scotland we found that only 14% of patients with COPD were taking beta-blockers for cardiovascular comorbidity.[37] Further evidence of a reluctance to prescribe beta-blockers in COPD was documented by Quint et al where 55% of patients who had a myocardial infarction were not prescribed a beta-blocker, with only 22% being prescribed on admission.[53] In the UK 64% of patients without COPD and acute coronary syndrome were prescribed beta-blockers as compared to 16% of similar patients with COPD who were prescribed beta-blockers.[54] Furthermore COPD was documented as a reason for withholding beta-blockers in 33% of patients who did not receive a beta-blocker, while non-cardiologists were 40% less likely to prescribe beta-blockers. In the United States, Chen et al found that elderly patients after an acute myocardial infarction were 62% less likely to be given beta-blockers in the presence of a history of treated COPD or asthma.[55] Initiating treatment with beta-blockers is not simple as it requires dose titration over a period of weeks along with monitoring of heart rate, blood pressure and perhaps spirometry, all of which take time, incurring extra healthcare costs. Moreover beta-blockers may be less well tolerated in older patients with co-existing comorbidities such as

1
2
3 diabetes, peripheral vascular disease and renal impairment, who are more prone to
4
5 postural hypotension.
6
7

8 9 **Choice of beta-blocker and effects on pulmonary function (Box 2)**

10
11 The mechanism of beta-blocker induced bronchoconstriction is thought to be due to
12
13 the effects of pre and post-junctional beta₂ receptor antagonism uncovering the
14
15 prevailing cholinergic tone via post-junctional smooth muscle muscarinic type 3
16
17 receptors, resulting in airway smooth muscle constriction.[57]
18
19

20
21 In a subgroup analysis of 2712 patients from the Tayside cohort who had serial
22
23 spirometry measures over 4 years, there was no deleterious effect of long term beta-
24
25 blocker use (88% were cardioselective) on either FEV₁ or FVC, even among the
26
27 more severe patients taking triple inhaled therapy, who had the greatest reductions
28
29 in exacerbations and mortality.[37] In a meta-analysis of randomized controlled trials
30
31 with cardio-selective beta-blockers there was no significant change in FEV₁
32
33 compared to placebo, when given either as single -2.1% (-6.1-2.0) or chronic dosing
34
35 -2.6% (-5.9-0.8), and also no significantly effect on the FEV₁ response to beta₂-
36
37 agonists[10]. In a randomized controlled trial of 27 patients with heart failure who
38
39 also had coexistent moderate to severe COPD, after 4 months of treatment there
40
41 was a 190ml significant fall FEV₁ between bisoprolol and placebo, while salbutamol
42
43 reversibility, symptoms and quality of life were unchanged.[60] In a comparison of
44
45 bisoprolol and placebo in patients with moderate to severe COPD, there was a
46
47 significantly worsening of dynamic hyperinflation during cycle endurance while
48
49 exercise duration was unaltered.[61] In a study comparing 24 COPD patients on
50
51 beta-blockers matched to patients not taking beta-blockers there was no difference
52
53
54
55
56
57
58
59
60

1
2
3 in exercise capacity or gas exchange despite lower heart rate and blood pressure, in
4
5 turn suggesting great oxygen delivery per heart beat.[62]
6

7
8 The beta-blockers currently licensed for heart failure are the beta₁ selective
9
10 bisoprolol, nebivolol, metoprolol and the non-selective carvedilol. As has already
11
12 been shown in heart failure [63] and asthma [49] it is important to slowly titrate up the
13
14 dose of beta-blocker to improve cardiovascular and pulmonary tolerability. Bisoprolol
15
16 has a licensed indication for use in heart failure and coronary artery disease and has
17
18 a beta_{1/2} receptor selectivity ratio of 14:1, which is higher than either atenolol (5:1) or
19
20 metoprolol (2:1).[64] In a cross-over study of 51 patients with COPD and heart
21
22 failure, directly comparing 6 weeks of bisoprolol, metoprolol and carvedilol,[65] FEV₁
23
24 was lowest with carvedilol and highest with bisoprolol with metoprolol in between. In
25
26 a randomized controlled trial comparing bisoprolol (mean dose 6.4mg) and carvedilol
27
28 (mean dose 47mg) in patients with heart failure and COPD, FEV₁ significantly
29
30 improved by 137ml with bisoprolol but not with carvedilol (30ml improvement).[66] In
31
32 15 mild to moderate COPD patients there was a significant worsening in airway
33
34 hyper-reactivity to methacholine challenge with metoprolol and propranolol but not
35
36 celiprolol compared to placebo, while the acute bronchodilator response to fenoterol
37
38 was only blunted by propranolol.[67]
39
40
41

42
43 Nebivolol has been shown to exhibit greater in vitro beta_{1/2} receptor selectivity than
44
45 bisoprolol in human myocardium.[68] In healthy volunteers attenuation of beta₂
46
47 receptor mediated terbutaline induced hypokalaemia was significantly greater with
48
49 bisoprolol 10mg or atenolol 50mg/100mg verses nebivolol 5mg, which in turn was
50
51 not different from placebo.[69] Nebivolol produced significant blunting of terbutaline
52
53 induced glucose and insulin responses compared to placebo in keeping with beta₂
54
55 receptor antagonism at the 5mg dose. However the relative beta_{1/2} selectivity cannot
56
57
58
59
60

1
2
3 be inferred since this would require comparison of beta-blocker doses which exhibit
4 the same degree of beta₁ antagonism as assessed by exercise heart rate
5 reduction,[70] which was not measured.
6
7

8
9 In a post hoc analysis of 2670 patients from the organized program to initiate
10 lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF), there
11 were no differences between selective and non-selective beta-blockers in terms of
12 lower mortality or re-hospitalization in patients with and without COPD.[72]
13 Carvedilol blocks both cardiac beta₁ and beta₂ receptors as well as exhibiting
14 peripheral vasodilatation due to alpha receptor blockade, which in addition to its anti-
15 oxidant activity [73] may explain its superiority verses metoprolol in heart failure in
16 one particular study, which may not have compared comparable doses.[63] Until
17 there is more convincing evidence to support the superiority of carvedilol in heart
18 failure, it would be prudent to choose a selective agent such as bisoprolol, nebivolol
19 or metoprolol due to their superior safety profile in COPD.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Long acting muscarinic antagonists such as tiotropium have been shown to obviate
35 bronchoconstriction even when using non-selective beta-blockade with propranolol in
36 asthmatic patients.[58] It is the more severe COPD patients who would in theory be
37 most at risk of beta-blocker induced bronchoconstriction. These patients would
38 usually already be taking concomitant LAMA and hence be protected from
39 bronchospasm. The relatively small degree of dose related beta₂ receptor
40 antagonism conferred for example by bisoprolol [59] would not be expected to result
41 in worsening of pulmonary function. It is also important to consider the potential
42 impact of beta₂ receptor genotype on the risk-benefit equation with beta-blockers in
43 COPD. It has been shown that asthmatic patients who possess one or two copies of
44 the arginine-16 beta₂ receptor polymorphism are more prone to propranolol induced
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 bronchoconstriction in terms of FEV₁ and airway resistance.[75] While the arginine-
4
5 16 polymorphism conferred a worse outcome on survival in patients receiving
6
7 metoprolol after an acute coronary syndrome,[76] it was not associated with survival
8
9 in HF patients treated with metoprolol or carvedilol.[77]
10

11 12 13 14 **Conclusions and the ways forward (Box 3)**

15
16 There are compelling reasons to use cardio-selective beta-blockers in patients with
17
18 COPD who have coexistent heart failure or are post myocardial infarction. Current
19
20 evidence would suggest that there remains a reticence to prescribe beta-blockers in
21
22 such patients because of a fear of adverse events, particularly worsened lung
23
24 function. Further prospective medium term safety studies are therefore required to
25
26 carefully follow effects of cardio-selective drugs on pulmonary function in patients
27
28 with more severe COPD by employing slow initial dose titration as well as evaluating
29
30 their interaction with long acting bronchodilators (ClinicalTrials.gov
31
32 Identifier:NCT01656005).
33
34
35

36
37 There is currently not sufficient evidence to advocate treatment with beta-blockers
38
39 for the prevention of exacerbations or exacerbation-related mortality. Long term
40
41 placebo controlled multicenter trials in COPD are indicated to confirm the benefits of
42
43 beta-blockers already seen on mortality and exacerbations in observational studies.
44
45 The key question to answer is whether the potential benefits of beta-blockers are
46
47 confined to those patients with known cardiovascular disease or are present in the
48
49 wider population who may have silent cardiovascular disease. Likewise, beta-
50
51 blockers are not currently indicated in COPD patients with diastolic dysfunction alone
52
53 where controlled trials are also warranted.
54
55
56
57
58
59
60

1
2
3 Beta-blockers are likely to be part of a more complex therapeutic jigsaw in
4
5 addressing the composite risk from different cardiovascular abnormalities in COPD,
6
7 and as has already been shown with heart failure there may be additive effects from
8
9 drugs acting on other neuro-hormonal pathways. This includes drugs which block the
10
11 renin-angiotensin system that may be particularly effective at regressing left
12
13 ventricular hypertrophy.[78] Dual angiotensin/neprilysin inhibition [79] may also
14
15 confer benefits by augmenting BNP levels and ameliorate the adverse effects of
16
17 hypoxic pulmonary vasoconstriction.[80, 81] Anti-platelet drugs might also be
18
19 beneficial for treating silent coronary artery disease in more severe COPD patients
20
21 who are oxygen dependent.[42] Pulmonologists have tended to focus on drugs
22
23 which act on the lung rather than the heart, because of the evidence supporting the
24
25 former. Perhaps now is time to look at the lungs' next door neighbour in the chest
26
27 and begin to address the unmet need of cardiac disease in COPD.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco

1
2
3 RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard
4 DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh
5 IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L,
6 Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R,
7 Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD,
8 Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235
9 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the
10 Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859): 2095-2128.
11
12

13
14
15
16
17
18
19
20
21 2. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic
22 obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression
23 analysis. *Lancet Respir Med* 2014; 2(1): 54-62.
24
25
26

27
28
29
30
31
32
33 3. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden
34 of chronic obstructive pulmonary disease in the USA. *Clinicoecon Outcomes Res*
35 2013; 5: 235-245.
36

37
38
39
40
41
42
43 4. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-
44 specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in
45 the United States for 2010 and projections through 2020. *Chest* 2015; 147(1): 31-45.
46

47
48
49
50
51
52
53
54
55
56
57
58
59
60 5. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agusti A, Criner GJ,
MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH,
Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson
HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M,
Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravittles M,
Meek PM, Papi A, Rabe KF, Roche N, Sciruba FC, Sethi S, Siafakas N, Sin DD,
Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J,
Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL, Research

- 1
2
3 AETFfC. An official american thoracic society/european respiratory society
4 statement: research questions in chronic obstructive pulmonary disease. *Am J*
5
6
7 *Respir Crit Care Med* 2015; 191(7): e4-e27.
8
9
10 6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and
11 cardiovascular disease. *Transl Res* 2013; 162(4): 237-251.
12
13
14 7. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ.
15 Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and
16 epidemiology. *Eur J Heart Fail* 2009; 11(2): 130-139.
17
18
19
20 8. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD
21 mortality: a systematic review and meta-analysis. *BMC Pulm Med* 2012; 12: 48.
22
23
24 9. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of
25 mortality and exacerbation in patients with COPD: a meta-analysis of observational
26 studies. *PLoS One* 2014; 9(11): e113048.
27
28
29
30 10. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective
31 beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. *Respir*
32 *Med* 2003; 97(10): 1094-1101.
33
34
35
36 11. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after
37 myocardial infarction: systematic review and meta regression analysis. *BMJ* 1999:
38 318(7200): 1730-1737.
39
40
41
42 12. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman
43 EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL,
44 Investigators RR. beta-Blocker use and clinical outcomes in stable outpatients with
45 and without coronary artery disease. *JAMA* 2012; 308(13): 1340-1349.
46
47
48
49 13. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM,
50 Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-
51
52
53
54
55
56
57
58
59
60

1
2
3 Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W,
4
5 Evaluation of CLtIPSEi. Coronary artery calcification is increased in patients with
6
7 COPD and associated with increased morbidity and mortality. *Thorax* 2014; 69(8):
8
9 718-723.

10
11 14. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of
12
13 ischemic heart disease on symptoms, health status, and exacerbations in patients
14
15 with COPD. *Chest* 2012; 141(4): 851-857.

16
17 15. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN,
18
19 Garcha DS, Wedzicha JA, Hurst JR. Cardiovascular risk, myocardial injury, and
20
21 exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*
22
23 2013; 188(9): 1091-1099.

24
25 16. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor
26
27 J, McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W.
28
29 Diagnosis of myocardial infarction following hospitalisation for exacerbation of
30
31 COPD. *Eur Respir J* 2012; 39(5): 1097-1103.

32
33 17. Cargill RI, Kiely DG, Lipworth BJ. Adverse effects of hypoxaemia on diastolic
34
35 filling in humans. *Clin Sci (Lond)* 1995; 89(2): 165-169.

36
37 18. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal
38
39 myocardial repolarisation in response to hypoxaemia and fenoterol. *Thorax* 1995:
40
41 50(10): 1062-1066.

42
43 19. Kiely DG, Cargill RI, Lipworth BJ. Cardiopulmonary interactions of salbutamol
44
45 and hypoxaemia in healthy young volunteers. *Br J Clin Pharmacol* 1995; 40(4): 313-
46
47 318.

- 1
2
3 20. Newnham DM, Wheeldon NM, Lipworth BJ, McDevitt DG. Single dosing
4 comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and
5 salbutamol in normal subjects. *Thorax* 1993; 48(6): 656-658.
6
7
8
9
10 21. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van
11 Tassell B, Mukherjee D, Lichstein E. Benefits of beta blockers in patients with heart
12 failure and reduced ejection fraction: network meta-analysis. *BMJ* 2013; 346: f55.
13
14 22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
15 *Lancet* 1999; 353(9146): 9-13.
16
17
18
19
20 23. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P,
21 Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,
22 Carvedilol Prospective Randomized Cumulative Survival Study G. Effect of carvedilol
23 on the morbidity of patients with severe chronic heart failure: results of the carvedilol
24 prospective randomized cumulative survival (COPERNICUS) study. *Circulation*
25 2002; 106(17): 2194-2199.
26
27
28
29
30 24. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
31 Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*
32 1999; 353(9169): 2001-2007.
33
34
35
36
37
38
39
40 25. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J,
41 McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary
42 of Beta-blockers and Beta-agonists. *J Am Coll Cardiol* 2011; 57(21): 2127-2138.
43
44
45
46
47 26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart
48 failure with preserved ejection fraction: a meta-analysis. *Heart Fail Rev* 2015; 20(2):
49 193-201.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Short PM, Anderson WJ, Elder DH, Struthers AD, Lipworth BJ. Impact of Left
4 Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. *Lung*
5 2015.
6
7
8
9 28. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, Sainty JM,
10 Orehek J. Left atrial and ventricular filling in chronic obstructive pulmonary disease.
11 An echocardiographic and Doppler study. *Am J Respir Crit Care Med* 2000; 162(2 Pt
12 1): 670-675.
13
14
15
16
17
18 29. Funk GC, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Left
19 ventricular diastolic dysfunction in patients with COPD in the presence and absence
20 of elevated pulmonary arterial pressure. *Chest* 2008; 133(6): 1354-1359.
21
22
23
24
25 30. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised
26 wedge pressure on exercise in chronic obstructive pulmonary disease. *Am Rev*
27 *Respir Dis* 1988; 138(2): 350-354.
28
29
30
31 31. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D,
32 Hueper K, Parikh MA, Gomes AS, Michos ED, Lima JA, Barr RG. Impaired left
33 ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-
34 Ethnic Study of Atherosclerosis COPD Study. *Chest* 2013; 144(4): 1143-1151.
35
36
37
38
39
40 41 32. Cuttica MJ, Colangelo LA, Shah SJ, Lima J, Kishi S, Arynchyn A, Jacobs DR,
42 Jr., Thyagarajan B, Liu K, Lloyd-Jones D, Kalhan R. Loss of Lung Health from Young
43 Adulthood and Cardiac Phenotypes in Middle Age. *Am J Respir Crit Care Med* 2015;
44 192(1): 76-85.
45
46
47
48
49 50 33. Alter P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, Koczulla
51 AR. Airflow limitation in COPD is associated with increased left ventricular wall stress
52 in coincident heart failure. *Respir Med* 2015.
53
54
55
56
57
58
59
60

- 1
2
3 34. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality
4 in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012; 67(11):
5 970-976.
6
7
8
9
10 35. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M,
11 Magnussen H. Decreasing cardiac chamber sizes and associated heart dysfunction
12 in COPD: role of hyperinflation. *Chest* 2010; 138(1): 32-38.
13
14
15
16 36. Heindl S, Lehnert M, Criege CP, Hasenfuss G, Andreas S. Marked sympathetic
17 activation in patients with chronic respiratory failure. *Am J Respir Crit Care Med*
18 2001; 164(4): 597-601.
19
20
21
22
23 37. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta
24 blockers in treatment of chronic obstructive pulmonary disease: a retrospective
25 cohort study. *BMJ* 2011; 342: d2549.
26
27
28
29
30 38. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta
31 blockers and the risk of death in hospitalised patients with acute exacerbations of
32 COPD. *Thorax* 2008; 63(4): 301-305.
33
34
35
36 39. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may
37 reduce mortality and risk of exacerbations in patients with chronic obstructive
38 pulmonary disease. *Archives of internal medicine* 2010; 170(10): 880-887.
39
40
41
42
43 40. Andell P, Erlinge D, Smith JG, Sundstrom J, Lindahl B, James S, Koul S.
44 beta-blocker use and mortality in COPD patients after myocardial infarction: a
45 Swedish nationwide observational study. *J Am Heart Assoc* 2015; 4(4).
46
47
48
49 41. Puente-Maestu L, Calle M, Ortega-Gonzalez A, Fuster A, Gonzalez C,
50 Marquez-Martin E, Marcos-Rodriguez PJ, Calero C, Rodriguez-Hermosa JL, Malo de
51 Molina R, Aburto M, Sobradillo P, Alcazar B, Tirado-Conde G, Group G. Multicentric
52
53
54
55
56
57
58
59
60

1
2
3 study on the beta-blocker use and relation with exacerbations in COPD. *Respir Med*
4
5 2014; 108(5): 737-744.

6
7 42. Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on
8 mortality in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care*
9
10
11
12 *Med* 2013; 187(7): 715-720.

13
14 43. Bhatt SP, Wells JM, Kinney GL, Washko GR, Jr., Budoff M, Kim YI, Bailey
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
beta-Blockers are associated with a reduction in COPD exacerbations. *Thorax* 2015.

44. von Haehling S, Schefold JC, Jankowska E, Doehner W, Springer J,
Strohschein K, Genth-Zotz S, Volk HD, Poole-Wilson P, Anker SD. Leukocyte
redistribution: effects of beta blockers in patients with chronic heart failure. *PLoS*
One 2009; 4(7): e6411.

45. Dunzendorfer S, Wiedermann CJ. Modulation of neutrophil migration and
superoxide anion release by metoprolol. *J Mol Cell Cardiol* 2000; 32(6): 915-924.

46. Garlichs CD, Zhang H, Mugge A, Daniel WG. Beta-blockers reduce the
release and synthesis of endothelin-1 in human endothelial cells. *Eur J Clin Invest*
1999; 29(1): 12-16.

47. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD,
Wedzicha JA. Sputum and plasma endothelin-1 levels in exacerbations of chronic
obstructive pulmonary disease. *Thorax* 2001; 56(1): 30-35.

48. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche
Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic
exposure to beta-blockers attenuates inflammation and mucin content in a murine
asthma model. *Am J Respir Cell Mol Biol* 2008; 38(3): 256-262.

- 1
2
3 49. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-
4 controlled trial to evaluate chronic dosing effects of propranolol in asthma. *Am J*
5
6
7 *Respir Crit Care Med* 2013; 187(12): 1308-1314.
8
- 9 50. Anderson WJ, Short PM, Williamson PA, Manoharan A, Lipworth BJ. The
10 inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-
11 moderate persistent asthma. *Clin Sci (Lond)* 2014; 127(11): 635-643.
12
13
- 14 51. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K,
15 Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY,
16 Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH,
17 Schwitler J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,
18 Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society
19 of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-
20 Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C,
21 Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A,
22 Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA,
23 Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF,
24 Hardman S, lung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis
25 JT, Ponikowski P, Guidelines ESCCfP. ESC guidelines for the diagnosis and
26 treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis
27 and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of
28 Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of
29 the ESC. *Eur J Heart Fail* 2012; 14(8): 803-869.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
- 51 52. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes
52 PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R.
53 Global strategy for the diagnosis, management, and prevention of chronic
54
55
56
57
58
59
60

1
2
3 obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care*
4
5 *Med* 2013; 187(4): 347-365.

6
7 53. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA,
8
9 Smeeth L. Effect of beta blockers on mortality after myocardial infarction in adults
10
11 with COPD: population based cohort study of UK electronic healthcare records. *BMJ*
12
13 2013; 347: f6650.

14
15 54. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-
16
17 blockers in patients with ischaemic heart disease and concomitant chronic
18
19 obstructive pulmonary disease. *QJM* 2005; 98(7): 493-497.

20
21 55. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of
22
23 beta-blocker therapy after acute myocardial infarction in elderly patients with chronic
24
25 obstructive pulmonary disease or asthma. *J Am Coll Cardiol* 2001; 37(7): 1950-1956.

26
27 56. Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M,
28
29 Robertson M, Ford I, Investigators S. Clinical profiles and outcomes in patients with
30
31 chronic heart failure and chronic obstructive pulmonary disease: an efficacy and
32
33 safety analysis of SHIFT study. *Int J Cardiol* 2013; 170(2): 182-188.

34
35 57. Lipworth BJ, Williamson PA. Think the impossible: beta-blockers for treating
36
37 asthma. *Clin Sci (Lond)* 2010; 118(2): 115-120.

38
39 58. Short PM, Anderson WJ, Williamson PA, Lipworth BJ. Effects of intravenous
40
41 and oral beta-blockade in persistent asthmatics controlled on inhaled corticosteroids.
42
43 *Heart* 2014; 100(3): 219-223.

44
45 59. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the
46
47 beta 1-adrenoceptor selectivity of bisoprolol. *Eur J Clin Pharmacol* 1991; 40(2): 135-
48
49 139.

- 1
2
3 60. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG,
4
5 McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic
6
7 obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail* 2009:
8
9 11(7): 684-690.
10
11 61. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Senechal M, Poirier P,
12
13 Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in
14
15 chronic obstructive pulmonary disease. *Am J Cardiol* 2012: 110(2): 258-263.
16
17 62. Thirapatarapong W, Armstrong HF, Bartels MN. Exercise capacity and
18
19 ventilatory response during exercise in COPD patients with and without beta
20
21 blockade. *Lung* 2013: 191(5): 531-536.
22
23 63. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P,
24
25 Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag
26
27 A, Skene A, Carvedilol Or Metoprolol European Trial I. Comparison of carvedilol and
28
29 metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol
30
31 Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003:
32
33 362(9377): 7-13.
34
35 64. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human
36
37 beta1, beta2 and beta3 adrenoceptors. *Br J Pharmacol* 2005: 144(3): 317-322.
38
39 65. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman
40
41 CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients
42
43 with chronic heart failure and chronic obstructive pulmonary disease: a randomized
44
45 crossover trial. *J Am Coll Cardiol* 2010: 55(17): 1780-1787.
46
47 66. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences
48
49 between bisoprolol and carvedilol in patients with chronic heart failure and chronic
50
51
52
53
54
55
56
57
58
59
60

1
2
3 obstructive pulmonary disease: a randomized trial. *Respir Med* 2011; 105 Suppl 1:
4 S44-49.

5
6
7 67. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers
8 R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-
9
10 R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-
11
12 blockers. *Chest* 2005; 127(3): 818-824.

13
14 68. Bundkirchen A, Brixius K, Bolck B, Nguyen Q, Schwinger RH. Beta 1-
15
16 adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP
17
18 12.177 and [125I]iodocyanopindolol binding studies. *Eur J Pharmacol* 2003; 460(1):
19
20 19-26.

21
22
23 69. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity
24
25 of three beta1-selective beta-blockers. *J Clin Pharm Ther* 2003; 28(3): 179-186.

26
27 70. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial
28
29 agonist activity of celiprolol in normal subjects. *Br J Clin Pharmacol* 1992; 34(4): 337-
30
31 343.

32
33
34 71. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
35
36 Nebivolol: haemodynamic effects and clinical significance of combined beta-
37
38 blockade and nitric oxide release. *Drugs* 2010; 70(1): 41-56.

39
40 72. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM.
41
42 Association of beta-blocker use and selectivity with outcomes in patients with heart
43
44 failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). *Am J*
45
46 *Cardiol* 2013; 111(4): 582-587.

47
48
49 73. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E,
50
51 Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. beta-Blockers in hypertension,
52
53 diabetes, heart failure and acute myocardial infarction: a review of the literature.
54
55
56 *Open Heart* 2015; 2(1): e000230.
57
58
59
60

- 1
2
3 74. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
4 Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart
5 failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010: 376(9744):
6 875-885.
7
8
9
10
11 75. Anderson WJ, Short PM, Manoharan A, Lipworth JL, Lipworth BJ. Influence of
12 beta2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in
13 patients with persistent asthma. *Ann Allergy Asthma Immunol* 2014: 112(5): 475-
14 476.
15
16
17
18
19
20 76. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-
21 adrenergic receptor genotype and survival among patients receiving beta-blocker
22 therapy after an acute coronary syndrome. *Jama* 2005: 294(12): 1526-1533.
23
24
25
26
27 77. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B,
28 Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association
29 between adrenergic receptor genotypes and survival in heart failure patients treated
30 with carvedilol or metoprolol. *J Am Coll Cardiol* 2008: 52(8): 644-651.
31
32
33
34
35
36 78. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman
37 J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and
38 eplerenone/enalapril in patients with essential hypertension and left ventricular
39 hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003: 108(15):
40 1831-1838.
41
42
43
44
45
46
47 79. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,
48 Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H,
49 Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl*
50 *J Med* 2014: 371(11): 993-1004.
51
52
53
54
55
56
57
58
59
60

1
2
3 80. Cargill RI, Lipworth BJ. Acute effects of ANP and BNP on hypoxic pulmonary
4 vasoconstriction in humans. *Br J Clin Pharmacol* 1995; 40(6): 585-590.
5
6

7 81. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide
8 in cor pulmonale. Hemodynamic and endocrine effects. *Chest* 1996; 110(5): 1220-
9
10
11
12 1225.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Beta-blockers in COPD: time for reappraisal**
4
5

6
7 **Authors:** Dr Brian Lipworth¹, Prof Jadwiga Wedzicha², Prof Graham Devereux³,
8
9 Professor Jørgen Vestbo⁴, Dr Mark T. Dransfield⁵
10
11

12
13
14 **Affiliations:** ¹Scottish Centre for Respiratory Research, Ninewells Hospital and
15
16 Medical School, University of Dundee, Scotland, UK, ²Airways Disease
17
18 Section, National Heart & Lung Institute, Imperial College London, London, UK,
19
20 ³Applied Health Sciences, University of Aberdeen, Aberdeen, UK, ⁴Centre for
21
22 Respiratory Medicine and Allergy, University Hospital South Manchester NHS
23
24 Foundation Trust, University of Manchester, UK, ⁵Lung Health Center, Division of
25
26 Pulmonary, Allergy and Critical Care Medicine, University of Alabama at
27
28 Birmingham, Alabama, USA; Birmingham VA Medical Center, Alabama, USA
29
30
31
32
33

34 **Correspondence:** Dr Brian Lipworth, Scottish Centre for Respiratory Research,
35
36 Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY
37
38 b.j.lipworth@dundee.ac.uk
39
40
41
42

43 **Manuscript word count:** 3141
44
45
46

47 **Author contributions:** All authors contributed to the literature search, writing and
48
49 presentation of the manuscript, and approval of the final version.
50
51
52
53
54
55
56
57
58
59
60

“Take Home” message:

Beta-blockers (BB) are used for heart failure and after myocardial infarction but remain underused in COPD despite recommendations in guidelines.

Abstract

The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in COPD. The use of beta-blockers in COPD has been proposed because of their known cardio-protective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post myocardial infarction and in heart failure they remain underused due to concerns regarding potential bronchoconstriction even with cardio-selective drugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in older patients with COPD who have other comorbidities. Medium term prospective placebo controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long acting bronchodilator therapy. Several retrospective observational studies have shown impressive reductions in mortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long term prospective placebo controlled randomized controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease where the situation is less clear.

1
2
3 **Key words:** COPD, beta-blocker, coronary artery disease, heart failure,
4
5 exacerbations
6
7

8
9 **Abstract word count:** 198
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic obstructive pulmonary disease (COPD) is one of the world's leading causes of morbidity and is now the third leading cause of mortality amounting to 3 million deaths in 2010.[1, 2] Exacerbations in particular account for up to three quarters of the total costs due to COPD,[3] with attributable costs exceeding 30 billion USD.[4] A recent COPD taskforce statement [5] identified an unmet need in terms of finding drugs to treat common co-morbidities specifically mentioning the putative effects of beta-blockers on the cardiovascular burden and its associated impact on mortality. Cardiovascular comorbidity is common in patients with COPD due to smoking in addition to other shared risks including genetic susceptibility, systemic inflammation and ageing.[6] The prevalence of COPD in patients with heart failure ranges from 11-52% in North American patients and 9-41% in European patients.[7] The purpose of this article is to critically reappraise the current knowledge regarding beta-blockers in COPD looking at the current evidence for their therapeutic index and how this relates to management guidelines.

We have not attempted a systematic review or meta-analysis as described elsewhere,[8-10] but rather highlighted the key areas of clinical relevance for physicians who treat patients with COPD. In this article we have 1) considered the putative link between COPD and the heart in terms of potential targets for beta-blockers, 2) reviewed retrospective data linking use of beta-blockers to reduced exacerbations and mortality, 3) examined the unmet need for use of beta-blockers in patients with COPD and both known, and potentially unknown cardiovascular disease, 4) evaluated which beta-blocker to use based on their pharmacology and

1
2
3 impact on pulmonary function, and 5) attempted to draw conclusions about the
4
5 current clinical use of beta-blockers in COPD.
6
7
8
9

10 **COPD and the heart (Figure 1 and Box 1)**

11
12 The main accepted clinical indications for the use of beta-blockers in COPD are for
13
14 patients post myocardial infarction and for patients with heart failure. However, the
15
16 presence of untreated or unrecognized (i.e. silent) cardiovascular disease may
17
18 contribute to mortality in COPD and may also be an underlying causative factor in
19
20 exacerbations which can be difficult to separate from respiratory etiologies.[6] [7] It is
21
22 also possible, if not likely, that the burden of cardiovascular disease may be under-
23
24 rated by pulmonologists when treating COPD patients because symptoms are
25
26 presumed to be primarily driven by airflow obstruction, especially during
27
28 exacerbations.
29
30
31

32
33 The prevalence of left ventricular systolic dysfunction ranges between 10-46% in
34
35 patients with COPD and though the occurrence of heart failure with preserved left
36
37 ventricular ejection fraction is less clear, estimates in patients with severe COPD are
38
39 as high as 90%.[7] The benefits of beta-blockers in patients with heart failure due to
40
41 left ventricular systolic dysfunction are well established from pivotal trials as well as
42
43 meta-analysis.[21-24] The challenge in COPD may be more with respect to
44
45 diagnosis of heart failure with echocardiography where image acquisition is difficult
46
47 due to lung hyperinflation.[25]
48
49

50
51 Beta-blockers only have proven benefits in patients post myocardial infarction but not
52
53 in stable coronary arterial disease.[11, 12] Nevertheless, the presence of coronary
54
55 calcium on chest CT scans is associated with mortality in COPD,[13] and known
56
57 coronary arterial disease is also associated with longer exacerbations, more
58
59
60

1
2
3 dyspnoea, lower health status and exercise capacity in stable patients with
4 COPD.[14] There is also an acute increase in arterial stiffness particularly during
5 infective exacerbations of COPD, along with increases in cardiac enzymes especially
6 in patients with coronary arterial disease;[15] one study found that one in twelve
7 patients admitted to hospital with an exacerbation of COPD met the criteria for a
8 myocardial infarction.[16] The presence of coronary heart disease in COPD along
9 with the adverse effects of hypoxaemia [17] may be compounded by the positive
10 chronotropic effects of concomitant inhaled beta-agonist therapy,[18, 19] further
11 compromising cardiac reserve. It has been shown that even a low dose of a beta-1
12 selective antagonist such as atenolol might protect against chronotropic, inotropic
13 and electrocardiographic effects of inhaled beta-agonists which are mediated by
14 cardiac beta₂ receptor stimulation.[20]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Another potential target is diastolic dysfunction though a meta-analysis suggests that the beneficial effects of beta-blockers in such patients are less clear cut.[26] Several factors may contribute to the occurrence of impaired diastolic function in COPD.

Firstly, patients with COPD also appear to have a higher left ventricular mass (hypertrophy) even in the absence of left ventricular dilatation. Secondly, lung hyperinflation in COPD may cause cardiac compression reducing both left ventricular and atrial filling even in the absence of raised pulmonary arterial pressure.[28-30]

These factors, may also be compounded by the negative effects of hypoxaemia on diastolic filling.[31] [17]

In addition to these COPD related risks, patients with the disease commonly have other co-morbidities such as coronary artery disease, hypertension and diabetes, which can all adversely affect diastolic function. This was addressed in a recent prospective longitudinal study of healthy young adults followed over 25 years, where

1
2
3 a fall in the ratio of forced expiratory volume in one second to forced vital capacity
4 (FEV₁/FVC) was associated with reduced left atrial size and cardiac output.[32] Left
5
6
7 ventricular end diastolic and end systolic wall stress measured by magnetic
8
9
10 resonance imaging (MRI) is associated with increasing severity of airflow obstruction
11
12 in patients with COPD and coexistent heart failure.[33] Impaired left ventricular filling
13
14 is clinically important because it can eventually produce left atrial enlargement which
15
16 is a key risk factor for atrial fibrillation and associated mortality during exacerbations
17
18 of COPD.[34] Furthermore, the presence of impaired diastolic filling in patients with
19
20 COPD is also related to impaired walking distance.[35] Thus, the absence of
21
22 benefits of beta-blockers in diastolic dysfunction may not apply in COPD and
23
24 deserved re-evaluation in this patient group.
25
26
27
28

29 **Effects of beta-blockers on mortality and exacerbations**

30
31
32 Due to the high cardiovascular comorbidity in COPD from smoking along with
33
34 increased sympathetic drive due to hypoxaemia,[36] beta-blockers have been
35
36 proposed as a cogent therapeutic intervention for their known cardio-protective
37
38 effects in addition to reducing heart rate and improving systolic and diastolic
39
40 dysfunction. One of the fundamental issues with regards to more widespread use of
41
42 beta-blockers in COPD is the concern regarding beta₂ receptor antagonism and
43
44 associated airway smooth muscle constriction which may even occur with cardio-
45
46 selective agents which exhibit preferential beta₁ blockade, especially in more
47
48 susceptible severe patients with impaired respiratory reserve. The risk-benefit
49
50 equation in COPD becomes more favorable for patients who already have overt
51
52 cardiac disease such as heart failure or post myocardial infarction, where beta-
53
54 blockers have proven protective effects.[11, 21] There are, however, no data as to
55
56
57
58
59
60

1
2
3 the putative beneficial effects of beta-blockers in those COPD patients who may
4 have concomitant silent coronary arterial disease or heart failure.
5

6
7 Retrospective observational data have shown beneficial effects of beta-blockers in a
8 cohort of 5977 patients with COPD who were followed over a mean of 4.35 years
9 [37] where their use was associated with an overall 22% (95% confidence interval 8-
10 33) reduction in mortality. In a study b of 825 patients admitted to hospital for an
11 exacerbation of COPD, beta-blocker use among 142 patients was associated with a
12 61% (1-86) reduction in mortality.[38] Rutten et al showed 32% (17-44) and 29% (17-
13 40) reductions in mortality and exacerbations, respectively, conferred by taking beta-
14 blockers among 2230 patients with COPD followed up for a mean of 7.2 years.[39] In
15 a cohort study from Sweden of 4858 patients with COPD, those who were
16 discharged on a beta-blocker (84%) post myocardial infarction had 13% (2-22) lower
17 mortality.[40] In a retrospective report of 256 patients with COPD with either
18 coronary heart disease or heart failure, 58% were taking beta-blockers where there
19 was a 73% (50-85) reduction in the likelihood of being admitted to a hospital
20 emergency room.[41] In contrast, in an observational study using time dependent
21 analysis of 2249 severe oxygen dependent COPD patients there was a 19%
22 increase in mortality associated with taking beta-blockers.[42] However, in a
23 prospectively followed cohort of 3464 patients Bhatt et al found a 27% (10-40)
24 reduction in total exacerbations, while in GOLD 3/4 patients on home oxygen there
25 was a 67% reduction (42-81).[43]
26
27

28
29 In a 2012 meta-analysis of 9 retrospective cohort studies, the pooled estimate for
30 mortality reduction with beta-blockers was reported to be 31% (22-38).[8] In a
31 subsequent 2014 meta-analysis of 15 retrospective studies of 21,596 patients with
32 COPD, the pooled estimate for reduction in overall mortality conferred by beta-
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 blockers was 28% (17-37) and for exacerbations was 38% (18-58).[9] The reduction
4
5 in mortality was 36% (24-46) among the subgroup of patients (5 studies: 39%
6
7 weighting) with known coronary heart disease and 26% (7-42) in the subgroup with
8
9 known heart failure (3 studies: 18% weighting).
10

11 The beneficial effects of beta-blockers on exacerbations may involve other potential
12
13 non-cardiac mechanisms whereby beta-blockers could reduce COPD exacerbations.
14
15 In heart failure, use of cardioselective beta-blockers reduces systemic inflammatory
16
17 cytokine release such as IL-6 and alters leukocyte distribution which may also impact
18
19 inflammation during respiratory infections.[44] Beta-blockers have also been
20
21 reported to inhibit neutrophil chemotaxis and oxygen free radical production,[45]
22
23 while in human endothelial cells they have been reported to reduce the release of
24
25 endothelin-1, a bronchoconstrictor peptide implicated in the pathogenesis of COPD
26
27 exacerbations.[46, 47]
28
29
30

31 It is not possible to eliminate the possibility of residual confounding in the
32
33 observational studies suggesting beta-blockers may reduce exacerbations and
34
35 mortality in COPD and thus definitive randomized trials are needed. There is now a
36
37 planned placebo controlled trial powered for a reduction in exacerbations using
38
39 metoprolol over 1 year via the US COPD Clinical Research Network and funded by
40
41 the Department of Defense (Clinicaltrials.gov Identifier:NCT02587351).
42
43
44
45

46 This study will only exclude those patients with an absolute indication for beta-
47
48 blockers including an MI or revascularization procedure within three years or with an
49
50 ejection fraction <40%. However, it remains possible that this and similar studies
51
52 may run the risk of only including patients where beta-blockers are less efficacious.
53
54
55
56
57
58
59
60

The unmet cardiac need in COPD

Beta-blockers have an established position in the management of coronary artery disease while heart failure guidelines reinforce their use in patients with concomitant COPD.[51] Similarly, COPD management strategies also state that the benefits of selective beta-1 blocker treatment in heart failure clearly outweigh any potential risk associated with treatment even in patients with severe COPD.[52] Despite this guidance there is a reluctance to prescribe even cardio-selective beta-blockers in COPD, even in the presence of known cardiac disease because of persistent concerns regarding potential bronchoconstriction, especially in more severe patients. In a cohort from Scotland we found that only 14% of patients with COPD were taking beta-blockers for cardiovascular comorbidity.[37] Further evidence of a reluctance to prescribe beta-blockers in COPD was documented by Quint et al where 55% of patients who had a myocardial infarction were not prescribed a beta-blocker, with only 22% being prescribed on admission.[53] In the UK 64% of patients without COPD and acute coronary syndrome were prescribed beta-blockers as compared to 16% of similar patients with COPD who were prescribed beta-blockers.[54] Furthermore COPD was documented as a reason for withholding beta-blockers in 33% of patients who did not receive a beta-blocker, while non-cardiologists were 40% less likely to prescribe beta-blockers. In the United States, Chen et al found that elderly patients after an acute myocardial infarction were 62% less likely to be given beta-blockers in the presence of a history of treated COPD or asthma.[55] Initiating treatment with beta-blockers is not simple as it requires dose titration over a period of weeks along with monitoring of heart rate, blood pressure and perhaps spirometry, all of which take time, incurring extra healthcare costs. Moreover beta-blockers may be less well tolerated in older patients with co-existing comorbidities such as

1
2
3 diabetes, peripheral vascular disease and renal impairment, who are more prone to
4
5 postural hypotension.
6
7

9 **Choice of beta-blocker and effects on pulmonary function (Box 2)**

10
11 The mechanism of beta-blocker induced bronchoconstriction is thought to be due to
12
13 the effects of pre and post-junctional beta₂ receptor antagonism uncovering the
14
15 prevailing cholinergic tone via post-junctional smooth muscle muscarinic type 3
16
17 receptors, resulting in airway smooth muscle constriction.[57]
18
19

20
21 In a subgroup analysis of 2712 patients from the Tayside cohort who had serial
22
23 spirometry measures over 4 years, there was no deleterious effect of long term beta-
24
25 blocker use (88% were cardioselective) on either FEV₁ or FVC, even among the
26
27 more severe patients taking triple inhaled therapy, who had the greatest reductions
28
29 in exacerbations and mortality.[37] In a meta-analysis of randomized controlled trials
30
31 with cardio-selective beta-blockers there was no significant change in FEV₁
32
33 compared to placebo, when given either as single -2.1% (-6.1-2.0) or chronic dosing
34
35 -2.6% (-5.9-0.8), and also no significantly effect on the FEV₁ response to beta₂-
36
37 agonists[10]. In a randomized controlled trial of 27 patients with heart failure who
38
39 also had coexistent moderate to severe COPD, after 4 months of treatment there
40
41 was a 190ml significant fall FEV₁ between bisoprolol and placebo, while salbutamol
42
43 reversibility, symptoms and quality of life were unchanged.[60] In a comparison of
44
45 bisoprolol and placebo in patients with moderate to severe COPD, there was a
46
47 significantly worsening of dynamic hyperinflation during cycle endurance while
48
49 exercise duration was unaltered.[61] In a study comparing 24 COPD patients on
50
51 beta-blockers matched to patients not taking beta-blockers there was no difference
52
53
54
55
56
57
58
59
60

1
2
3 in exercise capacity or gas exchange despite lower heart rate and blood pressure, in
4
5 turn suggesting great oxygen delivery per heart beat.[62]
6

7
8 The beta-blockers currently licensed for heart failure are the beta₁ selective
9
10 bisoprolol, nebivolol, metoprolol and the non-selective carvedilol. As has already
11
12 been shown in heart failure [63] and asthma [49] it is important to slowly titrate up the
13
14 dose of beta-blocker to improve cardiovascular and pulmonary tolerability. Bisoprolol
15
16 has a licensed indication for use in heart failure and coronary artery disease and has
17
18 a beta_{1/2} receptor selectivity ratio of 14:1, which is higher than either atenolol (5:1) or
19
20 metoprolol (2:1).[64] In a cross-over study of 51 patients with COPD and heart
21
22 failure, directly comparing 6 weeks of bisoprolol, metoprolol and carvedilol,[65] FEV₁
23
24 was lowest with carvedilol and highest with bisoprolol with metoprolol in between. In
25
26 a randomized controlled trial comparing bisoprolol (mean dose 6.4mg) and carvedilol
27
28 (mean dose 47mg) in patients with heart failure and COPD, FEV₁ significantly
29
30 improved by 137ml with bisoprolol but not with carvedilol (30ml improvement).[66] In
31
32 15 mild to moderate COPD patients there was a significant worsening in airway
33
34 hyper-reactivity to methacholine challenge with metoprolol and propranolol but not
35
36 celiprolol compared to placebo, while the acute bronchodilator response to fenoterol
37
38 was only blunted by propranolol.[67]
39
40
41
42

43 Nebivolol has been shown to exhibit greater in vitro beta_{1/2} receptor selectivity than
44
45 bisoprolol in human myocardium.[68] In healthy volunteers attenuation of beta₂
46
47 receptor mediated terbutaline induced hypokalaemia was significantly greater with
48
49 bisoprolol 10mg or atenolol 50mg/100mg verses nebivolol 5mg, which in turn was
50
51 not different from placebo.[69] Nebivolol produced significant blunting of terbutaline
52
53 induced glucose and insulin responses compared to placebo in keeping with beta₂
54
55 receptor antagonism at the 5mg dose. However the relative beta_{1/2} selectivity cannot
56
57
58
59
60

1
2
3 be inferred since this would require comparison of beta-blocker doses which exhibit
4 the same degree of beta₁ antagonism as assessed by exercise heart rate
5 reduction,[70] which was not measured.
6
7

8
9 In a post hoc analysis of 2670 patients from the organized program to initiate
10 lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF), there
11 were no differences between selective and non-selective beta-blockers in terms of
12 lower mortality or re-hospitalization in patients with and without COPD.[72]
13 Carvedilol blocks both cardiac beta₁ and beta₂ receptors as well as exhibiting
14 peripheral vasodilatation due to alpha receptor blockade, which in addition to its anti-
15 oxidant activity [73] may explain its superiority verses metoprolol in heart failure in
16 one particular study, which may not have compared comparable doses.[63] Until
17 there is more convincing evidence to support the superiority of carvedilol in heart
18 failure, it would be prudent to choose a selective agent such as bisoprolol, nebivolol
19 or metoprolol due to their superior safety profile in COPD.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Long acting muscarinic antagonists such as tiotropium have been shown to obviate
35 bronchoconstriction even when using non-selective beta-blockade with propranolol in
36 asthmatic patients.[58] It is the more severe COPD patients who would in theory be
37 most at risk of beta-blocker induced bronchoconstriction. These patients would
38 usually already be taking concomitant LAMA and hence be protected from
39 bronchospasm. The relatively small degree of dose related beta₂ receptor
40 antagonism conferred for example by bisoprolol [59] would not be expected to result
41 in worsening of pulmonary function. It is also important to consider the potential
42 impact of beta₂ receptor genotype on the risk-benefit equation with beta-blockers in
43 COPD. It has been shown that asthmatic patients who possess one or two copies of
44 the arginine-16 beta₂ receptor polymorphism are more prone to propranolol induced
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 bronchoconstriction in terms of FEV₁ and airway resistance.[75] While the arginine-
4
5 16 polymorphism conferred a worse outcome on survival in patients receiving
6
7 metoprolol after an acute coronary syndrome,[76] it was not associated with survival
8
9 in HF patients treated with metoprolol or carvedilol.[77]
10

11 12 13 14 **Conclusions and the ways forward (Box 3)**

15
16 There are compelling reasons to use cardio-selective beta-blockers in patients with
17
18 COPD who have coexistent heart failure or are post myocardial infarction. Current
19
20 evidence would suggest that there remains a reticence to prescribe beta-blockers in
21
22 such patients because of a fear of adverse events, particularly worsened lung
23
24 function. Further prospective medium term safety studies are therefore required to
25
26 carefully follow effects of cardio-selective drugs on pulmonary function in patients
27
28 with more severe COPD by employing slow initial dose titration as well as evaluating
29
30 their interaction with long acting bronchodilators (ClinicalTrials.gov
31
32 Identifier:NCT01656005).
33
34
35

36 There is currently not sufficient evidence to advocate treatment with beta-blockers
37
38 for the prevention of exacerbations or exacerbation-related mortality. Long term
39
40 placebo controlled multicenter trials in COPD are indicated to confirm the benefits of
41
42 beta-blockers already seen on mortality and exacerbations in observational studies.
43
44 The key question to answer is whether the potential benefits of beta-blockers are
45
46 confined to those patients with known cardiovascular disease or are present in the
47
48 wider population who may have silent cardiovascular disease. Likewise, beta-
49
50 blockers are not currently indicated in COPD patients with diastolic dysfunction alone
51
52 where controlled trials are also warranted.
53
54
55
56
57
58
59
60

1
2
3 Beta-blockers are likely to be part of a more complex therapeutic jigsaw in
4
5 addressing the composite risk from different cardiovascular abnormalities in COPD,
6
7 and as has already been shown with heart failure there may be additive effects from
8
9 drugs acting on other neuro-hormonal pathways. This includes drugs which block the
10
11 renin-angiotensin system that may be particularly effective at regressing left
12
13 ventricular hypertrophy.[78] Dual angiotensin/neprolysin inhibition [79] may also
14
15 confer benefits by augmenting BNP levels and ameliorate the adverse effects of
16
17 hypoxic pulmonary vasoconstriction.[80, 81] Anti-platelet drugs might also be
18
19 beneficial for treating silent coronary artery disease in more severe COPD patients
20
21 who are oxygen dependent.[42] Pulmonologists have tended to focus on drugs
22
23 which act on the lung rather than the heart, because of the evidence supporting the
24
25 former. Perhaps now is time to look at the lungs' next door neighbour in the chest
26
27 and begin to address the unmet need of cardiac disease in COPD.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco

1
2
3 RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard
4 DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh
5 IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L,
6 Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R,
7 Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD,
8 Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235
9 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the
10 Global Burden of Disease Study 2010. *Lancet* 2012; 380(9859): 2095-2128.
11
12

13
14
15
16
17
18
19
20
21 2. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic
22 obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression
23 analysis. *Lancet Respir Med* 2014; 2(1): 54-62.
24
25

26
27
28 3. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden
29 of chronic obstructive pulmonary disease in the USA. *Clinicoecon Outcomes Res*
30 2013; 5: 235-245.
31
32

33
34 4. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-
35 specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in
36 the United States for 2010 and projections through 2020. *Chest* 2015; 147(1): 31-45.
37
38
39

40 5. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agusti A, Criner GJ,
41 MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH,
42 Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson
43 HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M,
44 Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravittles M,
45 Meek PM, Papi A, Rabe KF, Roche N, Sciruba FC, Sethi S, Siafakas N, Sin DD,
46 Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J,
47 Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL, Research
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 AETFfC. An official american thoracic society/european respiratory society
4
5 statement: research questions in chronic obstructive pulmonary disease. *Am J*
6
7 *Respir Crit Care Med* 2015: 191(7): e4-e27.
8
9
10 6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and
11
12 cardiovascular disease. *Transl Res* 2013: 162(4): 237-251.
13
14 7. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ.
15
16 Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and
17
18 epidemiology. *Eur J Heart Fail* 2009: 11(2): 130-139.
19
20
21 8. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD
22
23 mortality: a systematic review and meta-analysis. *BMC Pulm Med* 2012: 12: 48.
24
25 9. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of
26
27 mortality and exacerbation in patients with COPD: a meta-analysis of observational
28
29 studies. *PLoS One* 2014: 9(11): e113048.
30
31
32 10. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective
33
34 beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. *Respir*
35
36 *Med* 2003: 97(10): 1094-1101.
37
38
39 11. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after
40
41 myocardial infarction: systematic review and meta regression analysis. *BMJ* 1999:
42
43 318(7200): 1730-1737.
44
45 12. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman
46
47 EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL,
48
49 Investigators RR. beta-Blocker use and clinical outcomes in stable outpatients with
50
51 and without coronary artery disease. *JAMA* 2012: 308(13): 1340-1349.
52
53
54 13. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM,
55
56 Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-

1
2
3 Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W,
4
5 Evaluation of CLtIPSEi. Coronary artery calcification is increased in patients with
6
7 COPD and associated with increased morbidity and mortality. *Thorax* 2014; 69(8):
8
9 718-723.

10
11 14. Patel AR, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of
12
13 ischemic heart disease on symptoms, health status, and exacerbations in patients
14
15 with COPD. *Chest* 2012; 141(4): 851-857.

16
17 15. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN,
18
19 Garcha DS, Wedzicha JA, Hurst JR. Cardiovascular risk, myocardial injury, and
20
21 exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*
22
23 2013; 188(9): 1091-1099.

24
25 16. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor
26
27 J, McAlpine L, Chalmers G, Newby DE, Clark E, Macfarlane PW, Macnee W.
28
29 Diagnosis of myocardial infarction following hospitalisation for exacerbation of
30
31 COPD. *Eur Respir J* 2012; 39(5): 1097-1103.

32
33 17. Cargill RI, Kiely DG, Lipworth BJ. Adverse effects of hypoxaemia on diastolic
34
35 filling in humans. *Clin Sci (Lond)* 1995; 89(2): 165-169.

36
37 18. Kiely DG, Cargill RI, Grove A, Struthers AD, Lipworth BJ. Abnormal
38
39 myocardial repolarisation in response to hypoxaemia and fenoterol. *Thorax* 1995;
40
41 50(10): 1062-1066.

42
43 19. Kiely DG, Cargill RI, Lipworth BJ. Cardiopulmonary interactions of salbutamol
44
45 and hypoxaemia in healthy young volunteers. *Br J Clin Pharmacol* 1995; 40(4): 313-
46
47 318.

48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Newnham DM, Wheeldon NM, Lipworth BJ, McDevitt DG. Single dosing
4 comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and
5 salbutamol in normal subjects. *Thorax* 1993; 48(6): 656-658.
6
7
8
9
10 21. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van
11 Tassell B, Mukherjee D, Lichstein E. Benefits of beta blockers in patients with heart
12 failure and reduced ejection fraction: network meta-analysis. *BMJ* 2013; 346: f55.
13
14 22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
15
16 *Lancet* 1999; 353(9146): 9-13.
17
18
19
20 23. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P,
21 Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL,
22 Carvedilol Prospective Randomized Cumulative Survival Study G. Effect of carvedilol
23 on the morbidity of patients with severe chronic heart failure: results of the carvedilol
24 prospective randomized cumulative survival (COPERNICUS) study. *Circulation*
25 2002; 106(17): 2194-2199.
26
27
28
29
30 24. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
31 Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*
32 1999; 353(9169): 2001-2007.
33
34
35
36
37
38
39
40 25. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J,
41 McMurray JJ. Heart failure and chronic obstructive pulmonary disease the quandary
42 of Beta-blockers and Beta-agonists. *J Am Coll Cardiol* 2011; 57(21): 2127-2138.
43
44
45
46
47 26. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart
48 failure with preserved ejection fraction: a meta-analysis. *Heart Fail Rev* 2015; 20(2):
49 193-201.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Short PM, Anderson WJ, Elder DH, Struthers AD, Lipworth BJ. Impact of Left
4 Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. *Lung*
5 2015.
6
7
8
9
10 28. Boussuges A, Pinet C, Molenat F, Burnet H, Ambrosi P, Badier M, Sainty JM,
11 Orehek J. Left atrial and ventricular filling in chronic obstructive pulmonary disease.
12 An echocardiographic and Doppler study. *Am J Respir Crit Care Med* 2000; 162(2 Pt
13 1): 670-675.
14
15
16
17
18 29. Funk GC, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. Left
19 ventricular diastolic dysfunction in patients with COPD in the presence and absence
20 of elevated pulmonary arterial pressure. *Chest* 2008; 133(6): 1354-1359.
21
22
23
24
25 30. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised
26 wedge pressure on exercise in chronic obstructive pulmonary disease. *Am Rev*
27 *Respir Dis* 1988; 138(2): 350-354.
28
29
30
31 31. Smith BM, Prince MR, Hoffman EA, Bluemke DA, Liu CY, Rabinowitz D,
32 Hueper K, Parikh MA, Gomes AS, Michos ED, Lima JA, Barr RG. Impaired left
33 ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-
34 Ethnic Study of Atherosclerosis COPD Study. *Chest* 2013; 144(4): 1143-1151.
35
36
37
38
39 40 32. Cuttica MJ, Colangelo LA, Shah SJ, Lima J, Kishi S, Arynchyn A, Jacobs DR,
41 Jr., Thyagarajan B, Liu K, Lloyd-Jones D, Kalhan R. Loss of Lung Health from Young
42 Adulthood and Cardiac Phenotypes in Middle Age. *Am J Respir Crit Care Med* 2015;
43 192(1): 76-85.
44
45
46
47
48 49 33. Alter P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, Koczulla
50 AR. Airflow limitation in COPD is associated with increased left ventricular wall stress
51 in coincident heart failure. *Respir Med* 2015.
52
53
54
55
56
57
58
59
60

- 1
2
3 34. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality
4 in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2012; 67(11):
5 970-976.
6
7
8
9
10 35. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M,
11 Magnussen H. Decreasing cardiac chamber sizes and associated heart dysfunction
12 in COPD: role of hyperinflation. *Chest* 2010; 138(1): 32-38.
13
14
15
16 36. Heindl S, Lehnert M, Criege CP, Hasenfuss G, Andreas S. Marked sympathetic
17 activation in patients with chronic respiratory failure. *Am J Respir Crit Care Med*
18 2001; 164(4): 597-601.
19
20
21
22
23 37. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta
24 blockers in treatment of chronic obstructive pulmonary disease: a retrospective
25 cohort study. *BMJ* 2011; 342: d2549.
26
27
28
29
30 38. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta
31 blockers and the risk of death in hospitalised patients with acute exacerbations of
32 COPD. *Thorax* 2008; 63(4): 301-305.
33
34
35
36 39. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may
37 reduce mortality and risk of exacerbations in patients with chronic obstructive
38 pulmonary disease. *Archives of internal medicine* 2010; 170(10): 880-887.
39
40
41
42
43 40. Andell P, Erlinge D, Smith JG, Sundstrom J, Lindahl B, James S, Koul S.
44 beta-blocker use and mortality in COPD patients after myocardial infarction: a
45 Swedish nationwide observational study. *J Am Heart Assoc* 2015; 4(4).
46
47
48
49 41. Puente-Maestu L, Calle M, Ortega-Gonzalez A, Fuster A, Gonzalez C,
50 Marquez-Martin E, Marcos-Rodriguez PJ, Calero C, Rodriguez-Hermosa JL, Malo de
51 Molina R, Aburto M, Sobradillo P, Alcazar B, Tirado-Conde G, Group G. Multicentric
52
53
54
55
56
57
58
59
60

1
2
3 study on the beta-blocker use and relation with exacerbations in COPD. *Respir Med*
4
5 2014; 108(5): 737-744.
6

7
8 42. Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on
9
10 mortality in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care*
11
12 *Med* 2013; 187(7): 715-720.
13

14
15 43. Bhatt SP, Wells JM, Kinney GL, Washko GR, Jr., Budoff M, Kim YI, Bailey
16
17 WC, Nath H, Hokanson JE, Silverman EK, Crapo J, Dransfield MT, Investigators CO.
18
19 beta-Blockers are associated with a reduction in COPD exacerbations. *Thorax* 2015.
20

21
22 44. von Haehling S, Schefold JC, Jankowska E, Doehner W, Springer J,
23
24 Strohschein K, Genth-Zotz S, Volk HD, Poole-Wilson P, Anker SD. Leukocyte
25
26 redistribution: effects of beta blockers in patients with chronic heart failure. *PLoS*
27
28 *One* 2009; 4(7): e6411.
29

30
31 45. Dunzendorfer S, Wiedermann CJ. Modulation of neutrophil migration and
32
33 superoxide anion release by metoprolol. *J Mol Cell Cardiol* 2000; 32(6): 915-924.
34

35
36 46. Garlichs CD, Zhang H, Mugge A, Daniel WG. Beta-blockers reduce the
37
38 release and synthesis of endothelin-1 in human endothelial cells. *Eur J Clin Invest*
39
40 1999; 29(1): 12-16.
41

42
43 47. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD,
44
45 Wedzicha JA. Sputum and plasma endothelin-1 levels in exacerbations of chronic
46
47 obstructive pulmonary disease. *Thorax* 2001; 56(1): 30-35.
48

49
50 48. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche
51
52 Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic
53
54 exposure to beta-blockers attenuates inflammation and mucin content in a murine
55
56 asthma model. *Am J Respir Cell Mol Biol* 2008; 38(3): 256-262.
57
58
59
60

- 1
2
3 49. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized placebo-
4 controlled trial to evaluate chronic dosing effects of propranolol in asthma. *Am J*
5 *Respir Crit Care Med* 2013; 187(12): 1308-1314.
6
7
8
9
10 50. Anderson WJ, Short PM, Williamson PA, Manoharan A, Lipworth BJ. The
11 inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-
12 moderate persistent asthma. *Clin Sci (Lond)* 2014; 127(11): 635-643.
13
14
15
16 51. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K,
17 Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY,
18 Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH,
19 Schwitler J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,
20 Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society
21 of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-
22 Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C,
23 Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A,
24 Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA,
25 Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF,
26 Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis
27 JT, Ponikowski P, Guidelines ESCCfP. ESC guidelines for the diagnosis and
28 treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis
29 and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of
30 Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of
31 the ESC. *Eur J Heart Fail* 2012; 14(8): 803-869.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 52. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes
53 PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R.
54 Global strategy for the diagnosis, management, and prevention of chronic
55
56
57
58
59
60

1
2
3 obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care*
4
5 *Med* 2013; 187(4): 347-365.

6
7 53. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA,
8
9 Smeeth L. Effect of beta blockers on mortality after myocardial infarction in adults
10
11 with COPD: population based cohort study of UK electronic healthcare records. *BMJ*
12
13 2013; 347: f6650.

14
15 54. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-
16
17 blockers in patients with ischaemic heart disease and concomitant chronic
18
19 obstructive pulmonary disease. *QJM* 2005; 98(7): 493-497.

20
21 55. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of
22
23 beta-blocker therapy after acute myocardial infarction in elderly patients with chronic
24
25 obstructive pulmonary disease or asthma. *J Am Coll Cardiol* 2001; 37(7): 1950-1956.

26
27 56. Tavazzi L, Swedberg K, Komajda M, Bohm M, Borer JS, Lainscak M,
28
29 Robertson M, Ford I, Investigators S. Clinical profiles and outcomes in patients with
30
31 chronic heart failure and chronic obstructive pulmonary disease: an efficacy and
32
33 safety analysis of SHIFT study. *Int J Cardiol* 2013; 170(2): 182-188.

34
35 57. Lipworth BJ, Williamson PA. Think the impossible: beta-blockers for treating
36
37 asthma. *Clin Sci (Lond)* 2010; 118(2): 115-120.

38
39 58. Short PM, Anderson WJ, Williamson PA, Lipworth BJ. Effects of intravenous
40
41 and oral beta-blockade in persistent asthmatics controlled on inhaled corticosteroids.
42
43
44
45
46
47 *Heart* 2014; 100(3): 219-223.

48
49 59. Lipworth BJ, Irvine NA, McDevitt DG. A dose-ranging study to evaluate the
50
51 beta 1-adrenoceptor selectivity of bisoprolol. *Eur J Clin Pharmacol* 1991; 40(2): 135-
52
53
54 139.

55
56
57
58
59
60

- 1
2
3 60. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG,
4
5 McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic
6
7 obstructive pulmonary disease: a randomized controlled trial. *Eur J Heart Fail* 2009:
8
9 11(7): 684-690.
10
11
12 61. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Senechal M, Poirier P,
13
14 Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in
15
16 chronic obstructive pulmonary disease. *Am J Cardiol* 2012: 110(2): 258-263.
17
18 62. Thirapatarapong W, Armstrong HF, Bartels MN. Exercise capacity and
19
20 ventilatory response during exercise in COPD patients with and without beta
21
22 blockade. *Lung* 2013: 191(5): 531-536.
23
24
25 63. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P,
26
27 Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag
28
29 A, Skene A, Carvedilol Or Metoprolol European Trial I. Comparison of carvedilol and
30
31 metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol
32
33 Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003:
34
35 362(9377): 7-13.
36
37
38 64. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human
39
40 beta1, beta2 and beta3 adrenoceptors. *Br J Pharmacol* 2005: 144(3): 317-322.
41
42
43 65. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman
44
45 CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients
46
47 with chronic heart failure and chronic obstructive pulmonary disease: a randomized
48
49 crossover trial. *J Am Coll Cardiol* 2010: 55(17): 1780-1787.
50
51
52 66. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences
53
54 between bisoprolol and carvedilol in patients with chronic heart failure and chronic
55
56
57
58
59
60

1
2
3 obstructive pulmonary disease: a randomized trial. *Respir Med* 2011; 105 Suppl 1:
4 S44-49.

5
6
7 67. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers
8 R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-
9
10 R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-
11
12 blockers. *Chest* 2005; 127(3): 818-824.

13
14 68. Bundkirchen A, Brixius K, Bolck B, Nguyen Q, Schwinger RH. Beta 1-
15
16 adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP
17
18 12.177 and [125I]iodocyanopindolol binding studies. *Eur J Pharmacol* 2003; 460(1):
19
20 19-26.

21
22
23 69. Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity
24
25 of three beta1-selective beta-blockers. *J Clin Pharm Ther* 2003; 28(3): 179-186.

26
27
28 70. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial
29
30 agonist activity of celiprolol in normal subjects. *Br J Clin Pharmacol* 1992; 34(4): 337-
31
32 343.

33
34 71. Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
35
36 Nebivolol: haemodynamic effects and clinical significance of combined beta-
37
38 blockade and nitric oxide release. *Drugs* 2010; 70(1): 41-56.

39
40
41 72. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM.
42
43 Association of beta-blocker use and selectivity with outcomes in patients with heart
44
45 failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). *Am J*
46
47 *Cardiol* 2013; 111(4): 582-587.

48
49
50 73. DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E,
51
52 Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. beta-Blockers in hypertension,
53
54 diabetes, heart failure and acute myocardial infarction: a review of the literature.
55
56 *Open Heart* 2015; 2(1): e000230.

57
58
59
60

- 1
2
3 74. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
4 Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart
5 failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010: 376(9744):
6 875-885.
7
8
9
10
11 75. Anderson WJ, Short PM, Manoharan A, Lipworth JL, Lipworth BJ. Influence of
12 beta2-adrenoceptor 16 genotype on propranolol-induced bronchoconstriction in
13 patients with persistent asthma. *Ann Allergy Asthma Immunol* 2014: 112(5): 475-
14 476.
15
16
17
18
19
20 76. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-
21 adrenergic receptor genotype and survival among patients receiving beta-blocker
22 therapy after an acute coronary syndrome. *Jama* 2005: 294(12): 1526-1533.
23
24
25
26
27 77. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B,
28 Muhlestein JB, Donahue M, Liggett SB, Anderson JL, Kraus WE. Lack of association
29 between adrenergic receptor genotypes and survival in heart failure patients treated
30 with carvedilol or metoprolol. *J Am Coll Cardiol* 2008: 52(8): 644-651.
31
32
33
34
35
36 78. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman
37 J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and
38 eplerenone/enalapril in patients with essential hypertension and left ventricular
39 hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003: 108(15):
40 1831-1838.
41
42
43
44
45
46
47 79. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR,
48 Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P-H,
49 Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl*
50 *J Med* 2014: 371(11): 993-1004.
51
52
53
54
55
56
57
58
59
60

1
2
3 80. Cargill RI, Lipworth BJ. Acute effects of ANP and BNP on hypoxic pulmonary
4 vasoconstriction in humans. *Br J Clin Pharmacol* 1995; 40(6): 585-590.
5

6
7 81. Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide
8 in cor pulmonale. Hemodynamic and endocrine effects. *Chest* 1996; 110(5): 1220-
9 1225.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Potential cardiac targets for beta-blockers in COPD (Box 1)

- Improved left ventricular systolic and diastolic function
- Reduced left ventricular dilatation
- Protection against myocardial ischemia
- Reduced left ventricular mass
- Reduced heart rate
- Anti-arrhythmic effects
- Inhibition of myocyte apoptosis
- Protection against hypoxic sympathetic drive
- Protection against adverse effects of beta-agonists

Potential non-cardiac targets for beta-blockers in COPD

- Inhibition of endothelin-1 release
- Reduction in circulating pro-inflammatory cytokines
- Inhibition of neutrophil chemotaxis and respiratory burst
- Reduction in Goblet cell number and mucus release

Prescribing of beta-blockers in COPD for cardiovascular disease (Box 2)

- Beta-1 selective antagonists including metoprolol, bisoprolol and nebivolol exhibit dose related beta-2 receptor blockade
- Carvedilol is a non-selective beta-antagonist which is more likely to cause bronchoconstriction than beta-1 selective antagonists
- Slowly titrate the dose of beta-blockers at 1-2 weekly intervals up to the usual maintenance dose
- Monitor supine and erect blood pressure, heart rate and spirometry during dose titration
- Concomitant long-acting muscarinic antagonists may obviate potential bronchoconstriction
- Symptomatic bradycardia may occur if beta-blockers are used with other rate limiting drugs such as calcium blockers (e.g. verapamil, diltiazem), ivabradine or anti-arrhythmic agents (e.g. digoxin, amiodarone, flecainide)
- Symptomatic hypotension may occur when beta-blockers are used with other vasodilator drugs (e.g. angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, alpha receptor blockers)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Key messages (Box 3)

- Cardiovascular comorbidity, including coronary artery disease and heart failure, commonly coexists in COPD due to the effects of smoking, systemic inflammation, hypoxaemia and other shared risks.
- COPD may also be associated with impaired diastolic filling due to lung hyperinflation, which may be compounded by the negative lusitropic effects of hypoxaemia and left ventricular hypertrophy.
- The main indications for beta blockers in patients with COPD are post myocardial infarction and heart failure with reduced ejection fraction. Despite clear evidence beta-blockers improve outcomes in these COPD patients they remain significantly underused due to concerns about adverse respiratory effects, even with beta-1 selective antagonists.
- Meta-analyses of retrospective studies with beta-blockers in COPD have shown pooled estimates for reductions in mortality of 28% and exacerbations of 38%.
- Initiating treatment with beta-blockers requires careful dose titration and monitoring. This may be particularly relevant for patients with COPD who are often older and have other comorbidities that increase the risk of intolerance.
- Beta-1 selective antagonists such as bisoprolol, nebivolol and metoprolol are preferred to the non-selective carvedilol as they are less likely to produce bronchoconstriction in COPD.

- Long acting muscarinic antagonists, which are commonly used in COPD protect against the potential for bronchoconstriction due to dose related beta-2 receptor antagonism.
- The key unanswered question is whether beta-blockers may confer benefits on mortality and exacerbations in all patients with COPD including those with silent cardiovascular disease.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

European Respiratory Journal
 Cardio-pulmonary interactions in COPD



LA ↑ left atrial dilatation , LV ↓ : reduced LV filling LVH: left ventricular hypertrophy
 CAD: coronary artery disease, PoHT: pulmonary hypertension , RV ↓:reduced right ventricular filling
 RVH: right ventricular hypertrophy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43